Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

127 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a dose-finding, open-label, single agent study of RX-3117. Once the maximum tolerated dose is identified additional subjects will be treated in a dose expansion followed by a 2-stage Phase 2 study. Subjects will be treated for up to 8 cycles of therapy. A cycle will be 4 weeks. RX-3117 dosing will be 3 times each week for 3 weeks follow by 1 week off treatment. All subjects will be followed for at least 30 days after the last dose of RX-3117.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Metastatic Bladder Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

oncology tumor metastatic bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RX-3117

All subjects will receive RX-3117.

Group Type EXPERIMENTAL

RX-3117

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RX-3117

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females who are 18 years or older
* Able to swallow capsules
* Histological or cytological evidence of confirmed metastatic pancreatic or advanced bladder cancer
* Able to discontinue all anticancer therapies 2 weeks prior to study start
* Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors
* Life expectancy of at least 3 months
* ECOG performance status of 0 or 1
* Provide written informed consent

Exclusion Criteria

* Primary brain tumors or clinical evidence of active brain metastasis
* Systemic corticosteroid use within 7 days before planned start of study therapy
* Active infection requiring parenteral or oral antibiotics within 2 weeks before planned start of study therapy
* Uncontrolled diabetes as assessed by the investigator
* Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
* History of bone marrow of solid organ transplantation
* History of congestive heart failure, arrhythmias, acute coronary syndrome or torsades de pointes
* Any other medical, psychiatric, or social condition, which in the opinion of the investigator, would preclude participation in the study, pose an undue medical hazard, interfere with the conduct of the study, or interfere with interpretation of the study results
* Known hypersensitivity to gemcitabine, azacytidine or cytosine arabinoside
* Pregnant, planning a pregnancy or breast feeding during the study
* Concurrent participation in another therapeutic clinical trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ely Benaim, MD

Role: STUDY_DIRECTOR

Rexahn Pharmaceuticals, Inc.

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RX-3117-P1-01

Identifier Type: -

Identifier Source: org_study_id

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

RX-3117

RX-3117

Interventions

RX-3117

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Processa Pharmaceuticals

Responsible Party

Principal Investigators

Ely Benaim, MD

Locations

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Rexahn Site

Countries

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

Other Identifiers

RX-3117-P1-01